Large-cap Health Care company Moderna has logged a 2.6% change today on a trading volume of 1,453,226. The average volume for the stock is 7,530,373.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Based in Cambridge, United States the company has 5,600 full time employees and a market cap of $15,546,647,552.
Over the last 12 months MRNA shares have declined by -65.0%, which represents a difference of -89.5% when compared to the S&P 500. The stock's 52 week high is $170.47 per share and its 52 week low is $35.8. Based on Moderna's average net margin growth of 21.1% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 6,848,000 | -4,714,000 | -69 | -260.47 |
| 2022 | 19,263,000 | 8,362,000 | 43 | -34.85 |
| 2021 | 18,471,000 | 12,202,000 | 66 | 170.97 |
| 2020 | 803,000 | -747,000 | -93 | 89.15 |
| 2019 | 60,000 | -514,000 | -857 | -200.7 |
| 2018 | 135,068 | -384,734 | -285 |
